IWMB310 Breakfast Workshop – Clinical Impact of Utilizing Multiplex IHC and Critical Antibodies in Diagnosis of Breast, Prostate, and Lung Cancers
6:30–7:45 am
CME/CE NOT APPLICABLE
Multiplex IHC technology was developed to simultaneously detect two or more antibodies in about the same time as it takes to do a single antibody IHC procedure. This has been a critical success in the clinical laboratory. A single Multiplex IHC can replace up to five single antibodies, reducing labor and reagent costs by > 50%. A key feature of this technology is that precious patient tissue is conserved while simultaneously testing for morphology distinct markers. This results in the generation of superior diagnostic data of increased predictive value as well as reducing time to result. The results are clear: Multiplex IHC is easy to interpret and gives additional information to pathologists while increasing their confidence in the results.
This workshop will feature three speakers who will review the use of this technology in the assessment and diagnosis of breast, prostate, and lung carcinomas:
- Breast Cancer Diagnosis: Assessing interobserver and intraobserver variability in the diagnosis of atypical ductal hyperplasia
- Prostate Cancer Diagnosis: The clinical utility of incorporating the chromosomal translocation specific ERG monoclonal antibody into every prostate panel
- PulmoPanel – A panel of six antibodies to differentiate between adenocarcinoma (LADC) and squamous cell carcinoma (SqCC) of the lung with 93% sensitivity and 100% specificity.
Presenters:
Sunil Badve, MD, MBBS, FCAP
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Bloomington
Isabell A. Sesterhenn, MD
Department of Genitourinary Pathology, Armed Forces Institute of Pathology, Washington, DC
Rhonda Henshall-Powell, PhD
Director of Marketing and Education, Biocare Medical, Concord, California
Presented by 
The CAP does not endorse the content of the industry workshops, individual presenters, or sponsoring companies.